{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T15:51:59Z","timestamp":1791129119811,"version":"4.1.0"},"reference-count":121,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["IIRPSG-2024-01-01202"],"award-info":[{"award-number":["IIRPSG-2024-01-01202"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"DOI":"10.1007\/s11030-026-11603-5","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T10:12:32Z","timestamp":1781863952000},"page":"7811-7859","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pyrimidine derivatives as anticancer agents targeting kinases: design strategies, biological evaluation, and structure\u2013activity relationship insights"],"prefix":"10.1007","volume":"30","author":[{"family":"Manjushree BV","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1978-6029","authenticated-orcid":false,"given":"Gurubasavaraja Swamy Purawarga","family":"Matada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2763-5757","authenticated-orcid":false,"given":"Rohit","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Ghara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anguraj","family":"Moulishankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"key":"11603_CR1","unstructured":"Cancer: World Health Organization; 2025 [cited 2025 09\/10]. Available from: https:\/\/www.who.int\/health-topics\/cancer#tab=tab_1"},{"key":"11603_CR2","unstructured":"Global Cancer Burden Growing, Amidst Mounting Need for Services: World Health Organization; 2025 [cited 2025 09\/10]. Available from: https:\/\/www.who.int\/news\/item\/01-02-2024-global-cancer-burden-growing--amidst-mounting-need-for-services#:~:text=In%202022%2C%20there%20were%20an,women%20die%20from%20the%20disease"},{"issue":"1","key":"11603_CR3","first-page":"7","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. CA Cancer J Clin 72(1):7\u201333","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"11603_CR4","first-page":"409","volume":"72","author":"KD Miller","year":"2022","unstructured":"Miller KD, Nogueira L, Devasia T, Mariotto AB, Yabroff KR, Jemal A et al (2022) Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin 72(5):409\u2013436","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"11603_CR5","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1002\/ijc.33574","volume":"149","author":"G Roshandel","year":"2021","unstructured":"Roshandel G, Ferlay J, Ghanbari\u2010Motlagh A, Partovipour E, Salavati F, Aryan K et al (2021) Cancer in Iran 2008 to 2025: recent incidence trends and short\u2010term predictions of the future burden. Int J Cancer 149(3):594\u2013605","journal-title":"Int J Cancer"},{"issue":"5","key":"11603_CR6","first-page":"351","volume":"69","author":"J Ma","year":"2019","unstructured":"Ma J, Jemal A, Fedewa SA, Islami F, Lichtenfeld JL, Wender RC et al (2019) The American cancer society 2035 challenge goal on cancer mortality reduction. CA Cancer J Clin 69(5):351\u2013362","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"11603_CR7","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1002\/ijc.32810","volume":"147","author":"A Znaor","year":"2020","unstructured":"Znaor A, Skakkeb\u00e6k NE, Rajpert-De Meyts E, Laversanne M, Kuli\u0161 T, Gurney J et al (2020) Testicular cancer incidence predictions in Europe 2010\u20132035: a rising burden despite population ageing. Int J Cancer 147(3):820\u2013828","journal-title":"Int J Cancer"},{"issue":"1","key":"11603_CR8","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1186\/s12889-024-19104-6","volume":"24","author":"J-L Lin","year":"2024","unstructured":"Lin J-L, Lin J-X, Lin G-T, Huang C-M, Zheng C-H, Xie J-W et al (2024) Global incidence and mortality trends of gastric cancer and predicted mortality of gastric cancer by 2035. BMC Public Health 24(1):1763","journal-title":"BMC Public Health"},{"issue":"3","key":"11603_CR9","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jncc.2025.02.002","volume":"5","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Ji Y, Liu S, Li J, Wu J, Jin Q et al (2025) Global burden of female breast cancer: new estimates in 2022, temporal trend and future projections up to 2050 based on the latest release from GLOBOCAN. J Natl Cancer Center 5(3):287","journal-title":"J Natl Cancer Center"},{"key":"11603_CR10","unstructured":"World Health Organization (WHO)"},{"key":"11603_CR11","unstructured":"WHOs (WHO) (2024) Global breast cancer initiative (GBCI 2024) [cited 2024 13\/05]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/breast-cancer"},{"key":"11603_CR12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/978-3-031-44252-0_5","volume-title":"Biodiversity in agriculture: sustainability of soil, soil fauna and soil flora","author":"KP Nair","year":"2023","unstructured":"Nair KP (2023) Which are the threats to biodiversity? It\u2019s conservation and sustainability. Biodiversity in agriculture: sustainability of soil, soil fauna and soil flora. Springer, pp 57\u2013100"},{"issue":"4&5","key":"11603_CR13","doi-asserted-by":"publisher","first-page":"598","DOI":"10.4103\/ijmr.ijmr_1821_22","volume":"156","author":"K Sathishkumar","year":"2022","unstructured":"Sathishkumar K, Chaturvedi M, Das P, Stephen S, Mathur P (2022) Cancer incidence estimates for 2022 & projection for 2025: result from national cancer registry programme, India. Indian J Med Res 156(4&5):598\u2013607","journal-title":"Indian J Med Res"},{"issue":"5","key":"11603_CR14","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1093\/eurpub\/ckz216","volume":"30","author":"C Mattiuzzi","year":"2020","unstructured":"Mattiuzzi C, Lippi G (2020) Cancer statistics: a comparison between world health organization (WHO) and global burden of disease (GBD). Eur J Public Health 30(5):1026\u20131027","journal-title":"Eur J Public Health"},{"issue":"3","key":"11603_CR15","doi-asserted-by":"publisher","first-page":"140","DOI":"10.6004\/jnccn.2024.0019","volume":"22","author":"EM Schaeffer","year":"2024","unstructured":"Schaeffer EM, Srinivas S, Adra N, An Y, Bitting R, Chapin B et al (2024) Prostate cancer, version 3.2024: featured updates to the NCCN guidelines. J Natl Compr Cancer Net 22(3):140\u2013150","journal-title":"J Natl Compr Cancer Net"},{"issue":"3","key":"11603_CR16","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/jnci\/djab204","volume":"114","author":"P Brennan","year":"2022","unstructured":"Brennan P, Davey-Smith G (2022) Identifying novel causes of cancers to enhance cancer prevention: new strategies are needed. JNCI J Natl Cancer Inst 114(3):353\u2013360","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"4","key":"11603_CR17","doi-asserted-by":"publisher","first-page":"e214708-e","DOI":"10.1001\/jamanetworkopen.2021.4708","volume":"4","author":"L Rahib","year":"2021","unstructured":"Rahib L, Wehner MR, Matrisian LM, Nead KT (2021) Estimated projection of US cancer incidence and death to 2040. JAMA Netw Open 4(4):e214708-e","journal-title":"JAMA Netw Open"},{"issue":"5","key":"11603_CR18","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s00044-022-02880-4","volume":"31","author":"G Grover","year":"2022","unstructured":"Grover G, Pal R, Bhatia R, Yar MS, Nath R, Singh S et al (2022) Design, synthesis, and pharmacological evaluation of aryl oxadiazole linked 1, 2, 4-triazine derivatives as anticonvulsant agents. Med Chem Res 31(5):781\u2013793","journal-title":"Med Chem Res"},{"key":"11603_CR19","doi-asserted-by":"publisher","first-page":"100783","DOI":"10.1016\/j.apmt.2020.100783","volume":"20","author":"PC Sharma","year":"2020","unstructured":"Sharma PC, Sharma D, Sharma A, Bansal KK, Rajak H, Sharma S et al (2020) New horizons in benzothiazole scaffold for cancer therapy: advances in bioactivity, functionality, and chemistry. Appl Mater Today 20:100783","journal-title":"Appl Mater Today"},{"issue":"26","key":"11603_CR20","doi-asserted-by":"publisher","first-page":"e202301200","DOI":"10.1002\/slct.202301200","volume":"8","author":"R Pal","year":"2023","unstructured":"Pal R, Teli G, Swamy Purawarga Matada G, Sanjay Dhiwar P (2023) Nitrogen\u2010containing heterocyclic scaffolds as EGFR inhibitors: design approaches, molecular docking, and structure\u2010activity relationships. ChemistrySelect 8(26):e202301200","journal-title":"ChemistrySelect"},{"key":"11603_CR21","doi-asserted-by":"publisher","first-page":"106215","DOI":"10.1016\/j.bioorg.2022.106215","volume":"130","author":"GP Shenoy","year":"2023","unstructured":"Shenoy GP, Pal R, Matada GSP, Singh E, Raghavendra NM, Dhiwar PS (2023) Discoidin domain receptor inhibitors as anticancer agents: a systematic review on recent development of DDRs inhibitors, their resistance and structure activity relationship. Bioorg Chem 130:106215","journal-title":"Bioorg Chem"},{"key":"11603_CR22","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/978-981-99-1284-1_9","volume-title":"The quintessence of basic and clinical research and scientific publishing","author":"N Raghavendra","year":"2023","unstructured":"Raghavendra N, Kumar BP, Sasmal P, Teli G, Pal R, Gurubasavaraja Swamy P et al (2023) Designing studies in pharmaceutical and medicinal chemistry. The quintessence of basic and clinical research and scientific publishing. Springer, pp 125\u2013148"},{"key":"11603_CR23","doi-asserted-by":"publisher","first-page":"176013","DOI":"10.1016\/j.ejphar.2023.176013","volume":"958","author":"F Davodabadi","year":"2023","unstructured":"Davodabadi F, Sajjadi SF, Sarhadi M, Mirghasemi S, Hezaveh MN, Khosravi S et al (2023) Cancer chemotherapy resistance: mechanisms and recent breakthrough in targeted drug delivery. Eur J Pharmacol 958:176013","journal-title":"Eur J Pharmacol"},{"key":"11603_CR24","unstructured":"Cancer Chemotherapy: World Health Organization; 2025 [cited 2025 09\/10]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK564367\/#:~:text=Chemotherapeutic%20agents%20are%20commonly%20associated,of%20infections%20due%20to%20immunosuppression"},{"issue":"19","key":"11603_CR25","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.3390\/cells13191656","volume":"13","author":"M Hawash","year":"2024","unstructured":"Hawash M (2024) Advances in cancer therapy: a comprehensive review of CDK and EGFR inhibitors. Cells 13(19):1656","journal-title":"Cells"},{"issue":"1","key":"11603_CR26","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s43556-022-00110-2","volume":"3","author":"Q Li","year":"2022","unstructured":"Li Q, Li Z, Luo T, Shi H (2022) Targeting the PI3K\/AKT\/mTOR and RAF\/MEK\/ERK pathways for cancer therapy. Mol Biomed 3(1):47","journal-title":"Mol Biomed"},{"issue":"1","key":"11603_CR27","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13046-024-02981-5","volume":"43","author":"W Li","year":"2024","unstructured":"Li W, Zhang K, Wang W, Liu Y, Huang J, Zheng M et al (2024) Combined inhibition of HER2 and VEGFR synergistically improves therapeutic efficacy via PI3K-AKT pathway in advanced ovarian cancer. J Exp Clin Cancer Res 43(1):56","journal-title":"J Exp Clin Cancer Res"},{"key":"11603_CR28","unstructured":"Targeted Therapy to Treat Cancer: National Cancer Institute [cited 2025 09\/10]. Available from: https:\/\/www.cancer.gov\/about-cancer\/treatment\/types\/targeted-therapies#:~:text=Targeted%20therapy%20is%20a%20type,Learn%20more%20about%20monoclonal%20antibodies"},{"key":"11603_CR29","unstructured":"Targeted Therapy: American Cancer Society; 2025 [cited 2025 09\/10]. Available from: https:\/\/www.cancer.org\/cancer\/managing-cancer\/treatment-types\/targeted-therapy.html#:~:text=of%20targeted%20therapy?-,What%20is%20targeted%20therapy?,grow%2C%20like%20blood%20vessel%20cells"},{"key":"11603_CR30","unstructured":"Targeted Therapy: National Cancer Institute [cited 2025 09\/10]. Available from: https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-terms\/def\/targeted-therapy"},{"key":"11603_CR31","doi-asserted-by":"publisher","first-page":"108579","DOI":"10.1016\/j.pharmthera.2023.108579","volume":"254","author":"A Mushtaq","year":"2024","unstructured":"Mushtaq A, Wu P, Naseer MM (2024) Recent drug design strategies and identification of key heterocyclic scaffolds for promising anticancer targets. Pharmacol Ther 254:108579","journal-title":"Pharmacol Ther"},{"issue":"18","key":"11603_CR32","doi-asserted-by":"publisher","first-page":"9722","DOI":"10.3390\/ijms22189722","volume":"22","author":"S Maniam","year":"2021","unstructured":"Maniam S, Maniam S (2021) Small molecules targeting programmed cell death in breast cancer cells. Int J Mol Sci 22(18):9722","journal-title":"Int J Mol Sci"},{"issue":"2","key":"11603_CR33","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1007\/s11030-024-10907-8","volume":"29","author":"FF Hagar","year":"2025","unstructured":"Hagar FF, Abbas SH, Atef E, Abdelhamid D, Abdel\u2010Aziz M (2025) Benzimidazole scaffold as a potent anticancer agent with different mechanisms of action (2016\u20132023). Mol Divers 29(2):1821\u20131849","journal-title":"Mol Divers"},{"issue":"5","key":"11603_CR34","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1039\/D4MD00003J","volume":"15","author":"P Halder","year":"2024","unstructured":"Halder P, Rai A, Talukdar V, Das P, Lakkaniga NR (2024) Pyrazolopyridine-based kinase inhibitors for anti-cancer targeted therapy. RSC Med Chem 15(5):1452\u20131470","journal-title":"RSC Med Chem"},{"issue":"7","key":"11603_CR35","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1002\/jhet.4593","volume":"60","author":"A Vyas","year":"2023","unstructured":"Vyas A, Sahu B, Pathania S, Nandi NK, Chauhan G, Asati V et al (2023) An insight on medicinal attributes of pyrimidine scaffold: an updated review. J Heterocycl Chem 60(7):1081\u20131121","journal-title":"J Heterocycl Chem"},{"issue":"1","key":"11603_CR36","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2174\/1574892809666140917104502","volume":"10","author":"R Kaur","year":"2015","unstructured":"Kaur R, Kaur P, Sharma S, Singh G, Mehndiratta S, Bedi PMS et al (2015) Anti-cancer pyrimidines in diverse scaffolds: a review of patent literature. Recent Pat Anti-cancer Drug Discov 10(1):23\u201371","journal-title":"Recent Pat Anti-cancer Drug Discov"},{"issue":"2","key":"11603_CR37","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3390\/ph16020299","volume":"16","author":"A Kumar","year":"2023","unstructured":"Kumar A, Singh AK, Singh H, Vijayan V, Kumar D, Naik J et al (2023) Nitrogen containing heterocycles as anticancer agents: a medicinal chemistry perspective. Pharmaceuticals 16(2):299","journal-title":"Pharmaceuticals"},{"issue":"1","key":"11603_CR38","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3390\/ph17010104","volume":"17","author":"B Nammalwar","year":"2024","unstructured":"Nammalwar B, Bunce RA (2024) Recent advances in pyrimidine-based drugs. Pharmaceuticals 17(1):104","journal-title":"Pharmaceuticals"},{"key":"11603_CR39","doi-asserted-by":"publisher","first-page":"107780","DOI":"10.1016\/j.bioorg.2024.107780","volume":"153","author":"A Bhatnagar","year":"2024","unstructured":"Bhatnagar A, Pemawat G (2024) Anticancer and antibacterial activeness of fused pyrimidines: newfangled updates. Bioorg Chem 153:107780","journal-title":"Bioorg Chem"},{"issue":"10","key":"11603_CR40","first-page":"1258","volume":"17","author":"KN Venugopala","year":"2024","unstructured":"Venugopala KN, Kamat V (2024) Pyrimidines: a new versatile molecule in the drug development field, scope, and future aspects. Pharm Basel 17(10):1258","journal-title":"Pharm Basel"},{"key":"11603_CR41","unstructured":"Gray NS, Janne P, Choi HG, Jang J (2025) Pyrimidines as EGFR-inhibitors and methods of treating disorders United States patent US12331037B2 [cited 02 Jan 2026]"},{"key":"11603_CR42","unstructured":"Hu Z, He H, Zhang F, Zhong W, Zhu X (2025) CDK inhibitors United States patent US12285429B2 [Cited 02 Jan, 2026]"},{"key":"11603_CR43","unstructured":"Daemen A, Junttila MR, Maneval EC, Multani PS, Patel R (2025) Egfr inhibitor for treating cancers comprising atypical egfr mutations Australia patent AU2024267333A1 [Cited 02 Jan, 2026]"},{"key":"11603_CR44","unstructured":"Chen GP, Li Z, Zhang W, Yan C (2025) Novel pyrimidine compound as kinase inhibitors with biological activities on egfr mutants WIPO (PCT) patent WO2024064091A1 [Cited 02 Jan, 2026]"},{"key":"11603_CR45","unstructured":"Ankrom W, BM, Pandey A, Pearson P, Zalutskaya A (2024) Egfr inhibitors for treatment of cancer WIPO (PCT) patent WO2024097270A1 [Cited 02 Jan 2026]"},{"key":"11603_CR46","unstructured":"Kim SE, Lee SH, Lee YH, Kong YJ, Baek MS, Kim MJ, Jeon HM (2024) Novel pyrimidine derivative showing inhibition effect on growth of cancer cells United States patent US20240166663A1"},{"key":"11603_CR47","unstructured":"Angel Guzman-Perez BCM, White RD, Jean Jr DST (2023) Egfr inhibitors of formula (i) for use in methods of treating cancer having two or more mutations in egfr WIPO (PCT) patent WO2025076094A1 [Cited 02 Jan 2026]"},{"key":"11603_CR48","unstructured":"Gangjee A (2023) Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient United States patent US11618758B2 [Cited 02 Jan 2026]"},{"key":"11603_CR49","unstructured":"Bae IH, Kim JS, Choi JY, Kang SJ, Ahn YG, Suh KH (2020) Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same United States patent US10870639B2 [Cited 02 Jan 2026]"},{"issue":"7","key":"11603_CR50","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1158\/2159-8290.CD-21-1615","volume":"12","author":"M Wang","year":"2022","unstructured":"Wang M, Yang JC-H, Mitchell PL, Fang J, Camidge DR, Nian W et al (2022) Sunvozertinib, a selective EGFR inhibitor for previously treated non\u2013small cell lung cancer with EGFR exon 20 insertion mutations. Cancer Discov 12(7):1676\u20131689","journal-title":"Cancer Discov"},{"key":"11603_CR51","doi-asserted-by":"publisher","first-page":"i20","DOI":"10.1093\/annonc\/mdx704","volume":"29","author":"J Remon","year":"2018","unstructured":"Remon J, Steuer C, Ramalingam S, Felip E (2018) Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients. Ann Oncol 29:i20\u2013i27","journal-title":"Ann Oncol"},{"key":"11603_CR52","doi-asserted-by":"publisher","first-page":"129084","DOI":"10.1016\/j.bmcl.2022.129084","volume":"80","author":"W-S Huang","year":"2023","unstructured":"Huang W-S, Li F, Gong Y, Zhang Y, Youngsaye W, Xu Y et al (2023) Discovery of mobocertinib, a potent, oral inhibitor of EGFR exon 20 insertion mutations in non\u2013small cell lung cancer. Bioorg Med Chem Lett 80:129084","journal-title":"Bioorg Med Chem Lett"},{"issue":"9","key":"11603_CR53","doi-asserted-by":"publisher","first-page":"799","DOI":"10.3349\/ymj.2022.63.9.799","volume":"63","author":"J Lee","year":"2022","unstructured":"Lee J, Hong MH, Cho BC (2022) Lazertinib: on the way to its throne. Yonsei Med J 63(9):799","journal-title":"Yonsei Med J"},{"issue":"6","key":"11603_CR54","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1634\/theoncologist.2009-0274","volume":"15","author":"P Hamberg","year":"2010","unstructured":"Hamberg P, Verweij J, Sleijfer S (2010) (Pre-) clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor. Oncologist 15(6):539\u2013547","journal-title":"Oncologist"},{"key":"11603_CR55","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/B978-0-12-817868-3.00005-6","volume-title":"Improving the therapeutic ratio in head and neck cancer","author":"A Galstyan","year":"2020","unstructured":"Galstyan A, Cho J, Johnson DE, Grandis JR (2020) Modulation of the PI3K\/mTOR pathways. Improving the therapeutic ratio in head and neck cancer. Elsevier, Amsterdam, pp 89\u2013105"},{"issue":"6","key":"11603_CR56","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1097\/PPO.0000000000000414","volume":"25","author":"JR Brown","year":"2019","unstructured":"Brown JR (2019) Phosphatidylinositol 3 kinase \u03b4 inhibitors: present and future. Cancer J 25(6):394\u2013400","journal-title":"Cancer J"},{"issue":"1","key":"11603_CR57","doi-asserted-by":"publisher","first-page":"16030","DOI":"10.1038\/s41598-024-67126-2","volume":"14","author":"N Lorman-Carb\u00f3","year":"2024","unstructured":"Lorman-Carb\u00f3 N, Mart\u00ednez-S\u00e1ez O, Fernandez-Martinez A, Galv\u00e1n P, Chic N, Garcia-Fructuoso I et al (2024) Comparative biological activity of palbociclib and ribociclib in hormone receptor-positive breast cancer. Sci Rep 14(1):16030","journal-title":"Sci Rep"},{"issue":"81","key":"11603_CR58","doi-asserted-by":"publisher","first-page":"35226","DOI":"10.18632\/oncotarget.26215","volume":"9","author":"S Kim","year":"2018","unstructured":"Kim S, Tiedt R, Loo A, Horn T, Delach S, Kovats S et al (2018) The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models. Oncotarget 9(81):35226","journal-title":"Oncotarget"},{"key":"11603_CR59","doi-asserted-by":"publisher","first-page":"321","DOI":"10.2147\/DDDT.S137783","volume":"12","author":"SP Corona","year":"2018","unstructured":"Corona SP, Generali D (2018) Abemaciclib: a CDK4\/6 inhibitor for the treatment of HR+\/HER2\u2212 advanced breast cancer. Drug Des Dev Ther 12:321\u2013330","journal-title":"Drug Des Dev Ther"},{"issue":"6577","key":"11603_CR60","doi-asserted-by":"publisher","first-page":"eabc1495","DOI":"10.1126\/science.abc1495","volume":"375","author":"A Fassl","year":"2022","unstructured":"Fassl A, Geng Y, Sicinski P (2022) CDK4 and CDK6 kinases: from basic science to cancer therapy. Science 375(6577):eabc1495","journal-title":"Science"},{"issue":"2","key":"11603_CR61","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/j.1742-4658.2009.07448.x","volume":"277","author":"T Mitsudomi","year":"2010","unstructured":"Mitsudomi T, Yatabe Y (2010) Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J 277(2):301\u2013308","journal-title":"FEBS J"},{"key":"11603_CR62","volume-title":"Biochemistry, epidermal growth factor receptor","author":"MB Murphrey","year":"2023","unstructured":"Murphrey MB, Quaim L, Rahimi N, Varacallo M (2023) Biochemistry, epidermal growth factor receptor. StatPearls Publishing, Treasure Island"},{"key":"11603_CR63","doi-asserted-by":"publisher","first-page":"1258371","DOI":"10.3389\/fonc.2023.1258371","volume":"13","author":"DF Schultz","year":"2023","unstructured":"Schultz DF, Billadeau DD, Jois SD (2023) EGFR trafficking: effect of dimerization, dynamics, and mutation. Front Oncol 13:1258371","journal-title":"Front Oncol"},{"issue":"6","key":"11603_CR64","doi-asserted-by":"publisher","DOI":"10.1590\/1414-431x202010754","volume":"54","author":"FG Gomes","year":"2021","unstructured":"Gomes FG, Almeida VHd, Martins-Cardoso K, Martins-Dinis M, Rondon AMdR, Melo A et al (2021) Epidermal growth factor receptor regulates fibrinolytic pathway elements in cervical cancer: functional and prognostic implications. Braz J Med Biol Res 54(6):e10754","journal-title":"Braz J Med Biol Res"},{"issue":"5","key":"11603_CR65","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3390\/cancers9050052","volume":"9","author":"P Wee","year":"2017","unstructured":"Wee P, Wang Z (2017) Epidermal growth factor receptor cell proliferation signaling pathways. Cancers Basel 9(5):52","journal-title":"Cancers Basel"},{"key":"11603_CR66","doi-asserted-by":"publisher","first-page":"102150","DOI":"10.1016\/j.rechem.2025.102150","volume":"14","author":"BC Narasimhachar","year":"2025","unstructured":"Narasimhachar BC, Ravish A, Beeraka NM, Pookunoth BC, Basappa S, Vishwanath D et al (2025) Development of novel pyrimidine-thio-triazoles targeting EGFR in breast cancer cells via one-pot copper-catalyzed 1, 3-dipolar cycloaddition. Results Chem 14:102150","journal-title":"Results Chem"},{"key":"11603_CR67","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S490303","author":"M Wang","year":"2025","unstructured":"Wang M, Xia Z, Nie W, Wang C, Nie H, Zhang S et al (2025) Design, synthesis and evaluation of novel cyclopropanesulfonamide derivatives for the treatment of EGFRC797S mutation in non-small cell lung cancer. Drug Des Devel Ther. https:\/\/doi.org\/10.2147\/DDDT.S490303","journal-title":"Drug Des Devel Ther"},{"issue":"2","key":"11603_CR68","doi-asserted-by":"publisher","first-page":"270","DOI":"10.3390\/ph18020270","volume":"18","author":"F Reymova","year":"2025","unstructured":"Reymova F, Sever B, Topalan E, Sevimli-Gur C, Can M, Tuyun AF et al (2025) Design, synthesis, and mechanistic anticancer evaluation of new pyrimidine-tethered compounds. Pharmaceuticals Basel 18(2):270","journal-title":"Pharmaceuticals Basel"},{"key":"11603_CR69","doi-asserted-by":"publisher","first-page":"108467","DOI":"10.1016\/j.bioorg.2025.108467","volume":"160","author":"H Yao","year":"2025","unstructured":"Yao H, Yang K, Cao L, Ren Y, Hou P, Yan M et al (2025) Synthesis and evaluation of novel amino pyrimidine derivatives containing sulfonamide and their application as EGFR inhibitors. Bioorg Chem 160:108467","journal-title":"Bioorg Chem"},{"key":"11603_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2025.118224","author":"J Liu","year":"2025","unstructured":"Liu J, Qiu J, Wang C, Nie H, Wang M, Zhang S et al (2025) The new N2-phenyl-N4-5-(dimethylphosphinyl)-6-quinoxalinamine pyrimidine-2, 4-diamine derivatives as EGFR inhibitors to overcome C797S-mediated resistance. Bioorg Med Chem. https:\/\/doi.org\/10.1016\/j.bmc.2025.118224","journal-title":"Bioorg Med Chem"},{"key":"11603_CR71","doi-asserted-by":"publisher","DOI":"10.1002\/cbdv.202500549","author":"R Pal","year":"2025","unstructured":"Pal R, Matada GSP, Teli G, Akhtar MJ, Kumar B (2025) Design, synthesis, and molecular profiling of Pyrimidine\u2010Furan derivatives targeting EGFRWT, EGFRT790M, and EGFRL858R\/T790M\/C797S in NSCLC: in vitro and in silico evaluation. Chem Biodivers. https:\/\/doi.org\/10.1002\/cbdv.202500549","journal-title":"Chem Biodivers"},{"key":"11603_CR72","doi-asserted-by":"publisher","first-page":"141227","DOI":"10.1016\/j.molstruc.2024.141227","volume":"1327","author":"R Pal","year":"2025","unstructured":"Pal R, Matada GSP, Teli G, Chawla V, Chawla PA (2025) Design, synthesis, and biological evaluation of novel 4-(4-ethoxyphenyl)-6-(substituted-phenyl) pyrimidin-2-amine\/thiol\/hydroxy derivatives as EGFRWT and EGFRT790M inhibitors targeting NSCLC: in-vitro and in-silico exploration. J Mol Struct 1327:141227","journal-title":"J Mol Struct"},{"key":"11603_CR73","doi-asserted-by":"publisher","first-page":"130188","DOI":"10.1016\/j.bmcl.2025.130188","volume":"122","author":"H Wang","year":"2025","unstructured":"Wang H, Gui Y, Cui S, Long X, Fan W, Tang C (2025) Design, synthesis, and biological evaluation of novel aminopyrimidine derivatives as EGFR inhibitors. Bioorg Med Chem Lett 122:130188","journal-title":"Bioorg Med Chem Lett"},{"issue":"3","key":"11603_CR74","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1039\/D3RA05401B","volume":"14","author":"AI Hassaballah","year":"2024","unstructured":"Hassaballah AI, AboulMagd AM, Hemdan MM, Hekal MH, El-Sayed AA, Farag PS (2024) New pyrazolo [3, 4-d] pyrimidine derivatives as EGFR-TK inhibitors: design, green synthesis, potential anti-proliferative activity and P-glycoprotein inhibition. RSC Adv 14(3):1995\u20132015","journal-title":"RSC Adv"},{"issue":"6","key":"11603_CR75","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1134\/S1070363224060239","volume":"94","author":"G Jyothi","year":"2024","unstructured":"Jyothi G, Palabindela R, Narsimha S (2024) Synthesis, anti-breast cancer, and EGFR activity of novel Pyrido [2, 3-d] pyrimidine-piperazine-1, 2, 4-oxadiazoles. Russ J Gen Chem 94(6):1464\u20131474","journal-title":"Russ J Gen Chem"},{"issue":"28","key":"11603_CR76","doi-asserted-by":"publisher","first-page":"20120","DOI":"10.1039\/D4RA03157A","volume":"14","author":"DN Binjawhar","year":"2024","unstructured":"Binjawhar DN, Katouah HA, Alshaye NA, Alharthi J, Alsharif G, Elsaid FG et al (2024) Synthesis and biological research of new imidazolone-sulphonamide-pyrimidine hybrids as potential EGFR-TK inhibitors and apoptosis-inducing agents. RSC Adv 14(28):20120\u201320129","journal-title":"RSC Adv"},{"issue":"39","key":"11603_CR77","doi-asserted-by":"publisher","first-page":"28608","DOI":"10.1039\/D4RA04165H","volume":"14","author":"HM Abd El-Lateef","year":"2024","unstructured":"Abd El-Lateef HM, Ezelarab HA, Ali AM, Alsaggaf AT, Mahdi WA, Alshehri S et al (2024) Design and evaluation of sulfadiazine derivatives as potent dual inhibitors of EGFR WT and EGFR T790M: integrating biological, molecular docking, and ADMET analysis. RSC Adv 14(39):28608\u201328625","journal-title":"RSC Adv"},{"issue":"5","key":"11603_CR78","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1039\/D3MD00668A","volume":"15","author":"T Wang","year":"2024","unstructured":"Wang T, Gao Y, Wu F, Luo L, Ma J, Hu Y (2024) Coumarin\u2013furo [2, 3-d] pyrimidone hybrid molecules targeting human liver cancer cells: synthesis, anticancer effect, EGFR inhibition and molecular docking studies. RSC Med Chem 15(5):1565\u20131577","journal-title":"RSC Med Chem"},{"key":"11603_CR79","doi-asserted-by":"crossref","unstructured":"Yu Q (2024) Sorafenib analogue and its rearranged compound: design, synthesis, their in vitro anticancer activity and crystal structure of the rearranged compound dichloromethane solvate","DOI":"10.20944\/preprints202401.1715.v1"},{"key":"11603_CR80","doi-asserted-by":"publisher","first-page":"107394","DOI":"10.1016\/j.bioorg.2024.107394","volume":"147","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Tong L, Yan F, Huang P, Zhu C-L, Pan C (2024) Design, synthesis, and antitumor activity evaluation of potent fourth-generation EGFR inhibitors for treatment of osimertinib resistant non-small cell lung cancer (NSCLC). Bioorg Chem 147:107394","journal-title":"Bioorg Chem"},{"key":"11603_CR81","doi-asserted-by":"publisher","first-page":"129648","DOI":"10.1016\/j.bmcl.2024.129648","volume":"101","author":"C Tang","year":"2024","unstructured":"Tang C, Wang J, Wang D, Wang H, Cui S, Xiao T et al (2024) Design, synthesis and biological evaluation of 2-phenylaminopyrimidine derivatives as EGFR inhibitors. Bioorg Med Chem Lett 101:129648","journal-title":"Bioorg Med Chem Lett"},{"key":"11603_CR82","doi-asserted-by":"publisher","first-page":"175586","DOI":"10.1016\/j.ejphar.2023.175586","volume":"949","author":"S Ghalehbandi","year":"2023","unstructured":"Ghalehbandi S, Yuzugulen J, Pranjol MZI, Pourgholami MH (2023) The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF. Eur J Pharmacol 949:175586","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"11603_CR83","doi-asserted-by":"publisher","first-page":"38071","DOI":"10.1038\/s41598-025-21944-0","volume":"15","author":"SF Ahmed","year":"2025","unstructured":"Ahmed SF, Samin S, Mondal A, Islam MF, Laboni HA, Ela AA et al (2025) Computational analysis of miRNA mediated KDR gene regulation and natural VEGFR2 inhibitors from Persicaria hydropiper in hepatocellular carcinoma. Sci Rep 15(1):38071","journal-title":"Sci Rep"},{"issue":"1","key":"11603_CR84","first-page":"50","volume":"22","author":"AA Shah","year":"2021","unstructured":"Shah AA, Kamal MA, Akhtar S (2021) Tumor angiogenesis and VEGFR-2: mechanism, pathways and current biological therapeutic interventions. Curr Drug Metab 22(1):50\u201359","journal-title":"Curr Drug Metab"},{"issue":"4","key":"11603_CR85","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.3390\/molecules26041076","volume":"26","author":"NE Kaufman","year":"2021","unstructured":"Kaufman NE, Dhingra S, Jois SD, Vicente MdGH (2021) Molecular targeting of epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR). Molecules 26(4):1076","journal-title":"Molecules"},{"issue":"12","key":"11603_CR86","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1002\/jcb.30344","volume":"123","author":"A Ahmad","year":"2022","unstructured":"Ahmad A, Nawaz MI (2022) Molecular mechanism of VEGF and its role in pathological angiogenesis. J Cell Biochem 123(12):1938\u20131965","journal-title":"J Cell Biochem"},{"issue":"1","key":"11603_CR87","doi-asserted-by":"publisher","first-page":"e0316146","DOI":"10.1371\/journal.pone.0316146","volume":"20","author":"EB Elkaeed","year":"2025","unstructured":"Elkaeed EB, Elkady H, Khattab AM, Yousef RG, Al-Ghulikah HA, Husein DZ et al (2025) Integrated in silico and in vitro exploration of the anti-VEGFR-2 activities of a semisynthetic xanthine alkaloid inhibiting breast cancer. PLoS ONE 20(1):e0316146","journal-title":"PLoS ONE"},{"issue":"1","key":"11603_CR88","first-page":"437","volume":"67","author":"H Abdelmohsen","year":"2024","unstructured":"Abdelmohsen H, El Kerdawy AM (2024) Design, synthesis, molecular docking studies and in silico prediction of ADME properties of new 5-nitrobenzimidazole\/thiopyrimidine hybrids as anti-angiogenic agents targeting hepatocellular carcinoma. Egypt J Chem 67(1):437\u2013446","journal-title":"Egypt J Chem"},{"issue":"5","key":"11603_CR89","doi-asserted-by":"publisher","first-page":"188952","DOI":"10.1016\/j.bbcan.2023.188952","volume":"1878","author":"WY Su","year":"2023","unstructured":"Su WY, Tian LY, Guo LP, Huang LQ, Gao WY (2023) PI3K signaling-regulated metabolic reprogramming: from mechanism to application. Biochim Biophys Acta (BBA) Rev Cancer 1878(5):188952","journal-title":"Biochim Biophys Acta (BBA) Rev Cancer"},{"issue":"9","key":"11603_CR90","doi-asserted-by":"publisher","first-page":"4172","DOI":"10.62347\/KIVS3169","volume":"14","author":"Y Qi","year":"2024","unstructured":"Qi Y, Deng S-M, Wang K-S (2024) Receptor tyrosine kinases in breast cancer treatment: unraveling the potential. Am J Cancer Res 14(9):4172","journal-title":"Am J Cancer Res"},{"issue":"6","key":"11603_CR91","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1042\/BCJ20210004","volume":"478","author":"S Arcucci","year":"2021","unstructured":"Arcucci S, Ramos-Delgado F, Cayron C, Therville N, Gratacap M-P, Basset C et al (2021) Organismal roles for the PI3K\u03b1 and \u03b2 isoforms: their specificity, redundancy or cooperation is context-dependent. Biochem J 478(6):1199\u20131225","journal-title":"Biochem J"},{"issue":"4","key":"11603_CR92","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1158\/1541-7786.MCR-20-0818","volume":"19","author":"R Nussinov","year":"2021","unstructured":"Nussinov R, Zhang M, Tsai C-J, Jang H (2021) Phosphorylation and driver mutations in PI3K\u03b1 and PTEN autoinhibition. Mol Cancer Res 19(4):543\u2013548","journal-title":"Mol Cancer Res"},{"issue":"4","key":"11603_CR93","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1042\/BST20220866","volume":"51","author":"SJ Rodgers","year":"2023","unstructured":"Rodgers SJ, Mitchell CA, Ooms LM (2023) The mechanisms of class 1A PI3K and Wnt\/\u03b2-catenin coupled signaling in breast cancer. Biochem Soc Trans 51(4):1459\u20131472","journal-title":"Biochem Soc Trans"},{"issue":"16","key":"11603_CR94","doi-asserted-by":"publisher","first-page":"3949","DOI":"10.3390\/cancers13163949","volume":"13","author":"F Rascio","year":"2021","unstructured":"Rascio F, Spadaccino F, Rocchetti MT, Castellano G, Stallone G, Netti GS et al (2021) The pathogenic role of PI3K\/AKT pathway in cancer onset and drug resistance: an updated review. Cancers 13(16):3949","journal-title":"Cancers"},{"issue":"16","key":"11603_CR95","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.3390\/cancers13163979","volume":"13","author":"S Ikeda","year":"2021","unstructured":"Ikeda S, Kato T, Kenmotsu H, Sekine A, Baba T, Ogura T (2021) Current treatment strategies for non-small-cell lung cancer with comorbid interstitial pneumonia. Cancers 13(16):3979","journal-title":"Cancers"},{"key":"11603_CR96","doi-asserted-by":"publisher","first-page":"819128","DOI":"10.3389\/fonc.2022.819128","volume":"12","author":"Y Peng","year":"2022","unstructured":"Peng Y, Wang Y, Zhou C, Mei W, Zeng C (2022) PI3K\/Akt\/mTOR pathway and its role in cancer therapeutics: are we making headway? Front Oncol 12:819128","journal-title":"Front Oncol"},{"key":"11603_CR97","doi-asserted-by":"publisher","first-page":"141724","DOI":"10.1016\/j.molstruc.2025.141724","volume":"1334","author":"NA Edris","year":"2025","unstructured":"Edris NA, Kadry HH, Taher AT, El-Rashedy AA, Adly ME (2025) Development of some derivatives of pyrimidine-5-carbonitrile as inhibitors of PI3K and screening of their anticancer activity. J Mol Struct 1334:141724","journal-title":"J Mol Struct"},{"key":"11603_CR98","doi-asserted-by":"publisher","first-page":"139565","DOI":"10.1016\/j.molstruc.2024.139565","volume":"1319","author":"S Nakka","year":"2025","unstructured":"Nakka S, Chaitanya KS, Sengar S, Chandu A, Sankaranarayanan M, Sharma V et al (2025) Exploring 4-morpholinopyrrolo-[2, 3-d]-pyrimidine derivatives as novel anti-cancer agents: design, synthesis and biological studies. J Mol Struct 1319:139565","journal-title":"J Mol Struct"},{"issue":"1","key":"11603_CR99","doi-asserted-by":"publisher","first-page":"2304625","DOI":"10.1080\/14756366.2024.2304625","volume":"39","author":"NM Ahmed","year":"2024","unstructured":"Ahmed NM, Mohamed MS, Awad SM, El-tawab NAA, Gaballah MS, Said AM (2024) Design, synthesis, molecular modelling and biological evaluation of novel 6-amino-5-cyano-2-thiopyrimidine derivatives as potent anticancer agents against leukemia and apoptotic inducers. J Enzyme Inhib Med Chem 39(1):2304625","journal-title":"J Enzyme Inhib Med Chem"},{"key":"11603_CR100","doi-asserted-by":"publisher","first-page":"1467028","DOI":"10.3389\/fphar.2024.1467028","volume":"15","author":"D Huang","year":"2024","unstructured":"Huang D, Yang J, Zhang Q, Zhou X, Wang Y, Shang Z et al (2024) Design, synthesis, and biological evaluation of 2, 4-dimorpholinopyrimidine-5-carbonitrile derivatives as orally bioavailable PI3K inhibitors. Front Pharmacol 15:1467028","journal-title":"Front Pharmacol"},{"issue":"6","key":"11603_CR101","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.3390\/ijms22062806","volume":"22","author":"P \u0141ukasik","year":"2021","unstructured":"\u0141ukasik P, Baranowska-Bosiacka I, Kulczycka K, Gutowska I (2021) Inhibitors of cyclin-dependent kinases: types and their mechanism of action. Int J Mol Sci 22(6):2806","journal-title":"Int J Mol Sci"},{"issue":"1","key":"11603_CR102","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3390\/cancers14010153","volume":"14","author":"DV Ziegler","year":"2021","unstructured":"Ziegler DV, Huber K, Fajas L (2021) The intricate interplay between cell cycle regulators and autophagy in cancer. Cancers 14(1):153","journal-title":"Cancers"},{"issue":"1","key":"11603_CR103","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-02080-z","volume":"10","author":"I Pellarin","year":"2025","unstructured":"Pellarin I, Dall\u2019Acqua A, Favero A, Segatto I, Rossi V, Crestan N et al (2025) Cyclin-dependent protein kinases and cell cycle regulation in biology and disease. Signal Transduct Target Ther 10(1):11","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"11603_CR104","doi-asserted-by":"publisher","first-page":"5754","DOI":"10.3390\/ijms22115754","volume":"22","author":"T Zou","year":"2021","unstructured":"Zou T, Lin Z (2021) The involvement of ubiquitination machinery in cell cycle regulation and cancer progression. Int J Mol Sci 22(11):5754","journal-title":"Int J Mol Sci"},{"key":"11603_CR105","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/bs.apcsb.2023.02.001","volume":"135","author":"A Gupta","year":"2023","unstructured":"Gupta A, Dagar G, Chauhan R, Sadida HQ, Almarzooqi SK, Hashem S et al (2023) Cyclin-dependent kinases in cancer: role, regulation, and therapeutic targeting. Adv Protein Chem Struct Biol 135:21\u201355","journal-title":"Adv Protein Chem Struct Biol"},{"key":"11603_CR106","first-page":"1","volume":"8","author":"EA Alsalam","year":"2025","unstructured":"Alsalam EA, Awad HM, Abbass EM, Hafez HN, Assy MG, Ali AK et al (2025) TiO2 nanoparticles catalyzed synthesis, pharmacological evaluation, and molecular docking studies of new pyrido [2, 3-d] pyrimidine derivatives as CDK1 inhibitors. Chem Afr 8:1\u201315","journal-title":"Chem Afr"},{"key":"11603_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2025.108792","author":"HR Elgiushy","year":"2025","unstructured":"Elgiushy HR, Soliman ME, El-Khouly ME, Abouzid KA, Hammad SF (2025) Discovery of pyrazolo [1, 5-a] pyrimidines: synthesis, in silico insights, and anticancer activity via novel CDK2\/tubulin dual inhibition approach. Bioorg Chem. https:\/\/doi.org\/10.1016\/j.bioorg.2025.108792","journal-title":"Bioorg Chem"},{"issue":"3","key":"11603_CR108","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s44446-025-00010-w","volume":"33","author":"LS Al-Rasheed","year":"2025","unstructured":"Al-Rasheed LS, Ansari SA, Asiri HH, Bakheit AH, Al-Mehizia AA, Alsegiani AS et al (2025) Design, synthesis, biological evaluation and in silico studies of 2-anilino-4-(benzimidazol-1-yl) pyrimidine scaffold as antitumor agents. Saudi Pharm J 33(3):12","journal-title":"Saudi Pharm J"},{"key":"11603_CR109","doi-asserted-by":"publisher","first-page":"142009","DOI":"10.1016\/j.molstruc.2025.142009","volume":"1336","author":"BK Chagaleti","year":"2025","unstructured":"Chagaleti BK, Saravanan V, Oubella A, Alotaibi SH, Altharawi A, K MK (2025) Pyrazolopyrimidine fused thiazolidinone hybrids as CDK2 inhibitors: insights from pharmacophore modeling, docking, DFT and molecular dynamics simulations. J Mol Struct 1336:142009","journal-title":"J Mol Struct"},{"issue":"12","key":"11603_CR110","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.3390\/ph17121667","volume":"17","author":"MH Attia","year":"2024","unstructured":"Attia MH, Lasheen DS, Samir N, Taher AT, Abdel-Aziz HA, Abou El Ella DA (2024) Design, synthesis and molecular modeling of Pyrazolo [1, 5-a] pyrimidine derivatives as dual inhibitors of CDK2 and TRKA kinases with antiproliferative activity. Pharmaceuticals 17(12):1667","journal-title":"Pharmaceuticals"},{"issue":"9","key":"11603_CR111","first-page":"553","volume":"68","author":"MES Mohamed","year":"2025","unstructured":"Mohamed MES, Fatahala SS, Atya HB, Abd El-Hameed RH, Sayed AI, Aly O et al (2025) Synthesis, anti-cancer evaluation and in vitro study of some novel Pyr-rolo-pyrimidine scaffolds. Egypt J Chem 68(9):553\u2013564","journal-title":"Egypt J Chem"},{"issue":"1","key":"11603_CR112","doi-asserted-by":"publisher","first-page":"2169282","DOI":"10.1080\/14756366.2023.2169282","volume":"38","author":"B Yang","year":"2023","unstructured":"Yang B, Quan Y, Zhao W, Ji Y, Yang X, Li J et al (2023) Design, synthesis and biological evaluation of 2-((4-sulfamoylphenyl) amino)-pyrrolo [2, 3-d] pyrimidine derivatives as CDK inhibitors. J Enzyme Inhib Med Chem 38(1):2169282","journal-title":"J Enzyme Inhib Med Chem"},{"key":"11603_CR113","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2025.142586","author":"RG Yousef","year":"2025","unstructured":"Yousef RG, El-Metwally SA, Al Ward MMS, Alsfouk AA, Husein DZ, Soliman OA et al (2025) Discovery of new thieno [2, 3-d] pyrimidine-based dual VEGFR-2 and EGFR inhibitors for enhanced therapeutic efficacy in breast cancer. J Mol Struct. https:\/\/doi.org\/10.1016\/j.molstruc.2025.142586","journal-title":"J Mol Struct"},{"issue":"4","key":"11603_CR114","doi-asserted-by":"publisher","first-page":"267","DOI":"10.21608\/ejchem.2024.302958.9979","volume":"68","author":"WA Zaghary","year":"2025","unstructured":"Zaghary WA, Adel D, Nasr T, El-Adl K (2025) Design, sequential synthesis, kinase inhibitors comparative docking, md simulations, 99mTc-coupling and in-vivo studies of novel pyrazolopyrimidine derivatives. Egypt J Chem 68(4):267\u2013280","journal-title":"Egypt J Chem"},{"issue":"39","key":"11603_CR115","doi-asserted-by":"publisher","first-page":"28889","DOI":"10.1039\/D4RA05462H","volume":"14","author":"HT Abdel-Mohsen","year":"2024","unstructured":"Abdel-Mohsen HT, Nageeb AM (2024) Benzimidazole\u2013dioxoisoindoline conjugates as dual VEGFR-2 and FGFR-1 inhibitors: design, synthesis, biological investigation, molecular docking studies and ADME predictions. RSC Adv 14(39):28889\u201328903","journal-title":"RSC Adv"},{"key":"11603_CR116","doi-asserted-by":"publisher","first-page":"116607","DOI":"10.1016\/j.ejmech.2024.116607","volume":"275","author":"S Faizan","year":"2024","unstructured":"Faizan S, Wali AF, Talath S, Rehman MU, Sivamani Y, Nilugal KC et al (2024) Novel dihydropyrimidines as promising EGFR & HER2 inhibitors: insights from experimental and computational studies. Eur J Med Chem 275:116607","journal-title":"Eur J Med Chem"},{"key":"11603_CR117","doi-asserted-by":"publisher","first-page":"107185","DOI":"10.1016\/j.bioorg.2024.107185","volume":"145","author":"N Reda","year":"2024","unstructured":"Reda N, Mohamed KO, Abdou K, Helwa AA, Elshewy A (2024) Novel pyrimidine-5-carbonitriles as potential apoptotic and antiproliferative agents by dual inhibition of EGFRWT\/T790M and PI3k enzymes; design, synthesis, biological evaluation, and docking studies. Bioorg Chem 145:107185","journal-title":"Bioorg Chem"},{"issue":"32","key":"11603_CR118","doi-asserted-by":"publisher","first-page":"34358","DOI":"10.1021\/acsomega.4c01361","volume":"9","author":"LH Al-Wahaibi","year":"2024","unstructured":"Al-Wahaibi LH, Elshamsy AM, Ali TF, Youssif BG, Br\u00e4se S, Abdel-Aziz M et al (2024) Design and synthesis of new dihydropyrimidine derivatives with a cytotoxic effect as dual EGFR\/VEGFR-2 inhibitors. ACS Omega 9(32):34358\u201334369","journal-title":"ACS Omega"},{"key":"11603_CR119","doi-asserted-by":"publisher","first-page":"1498104","DOI":"10.3389\/fchem.2024.1498104","volume":"12","author":"YA Mostafa","year":"2024","unstructured":"Mostafa YA, Assoud JA, Desoky AY, Mohamady S, Mohamed NM, Salem OI et al (2024) New series of 4, 6-diaryl pyrimidines: facile synthesis and antiproliferative activity as dual EGFR\/VEGFR-2 inhibitors. Front Chem 12:1498104","journal-title":"Front Chem"},{"issue":"16","key":"11603_CR120","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1080\/17568919.2024.2366147","volume":"16","author":"FM Krakisha","year":"2024","unstructured":"Krakisha FM, Othman DI, El Husseiny WM, Nasr MN (2024) New pyridopyrimidine derivatives as dual EGFR and CDK4\/cyclin D1 inhibitors: synthesis, biological screening and molecular modeling. Future Med Chem 16(16):1633\u20131648","journal-title":"Future Med Chem"},{"issue":"2","key":"11603_CR121","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1039\/D3MD00693J","volume":"15","author":"GS Rady","year":"2024","unstructured":"Rady GS, El Deeb MA, Sarg MT, Taher AT, Helwa AA (2024) Design, synthesis and biological evaluation of novel morpholinopyrimidine-5-carbonitrile derivatives as dual PI3K\/mTOR inhibitors. RSC Med Chem 15(2):733\u2013752","journal-title":"RSC Med Chem"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-026-11603-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-026-11603-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-026-11603-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T15:02:49Z","timestamp":1791126169000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-026-11603-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":121,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["11603"],"URL":"https:\/\/doi.org\/10.1007\/s11030-026-11603-5","relation":{},"ISSN":["1573-501X"],"issn-type":[{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"assertion":[{"value":"7 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}